サマリー

特発性肺線維症の世界市場は、2020年には31億2,608万ドルとなり、2021年から2030年にかけて年平均成長率7.0%を記録し、2030年には61億6,937万ドルに達すると予測されています。

特発性肺線維症は、慢性肺疾患、または肺の組織が時間の経過とともに厚く硬くなる疾患である。肺の組織が厚くなった結果、脳や他の臓器に最適な酸素が行き渡らなくなります。この疾患は、肺に瘢痕組織（線維化）を蓄積させ、肺が効果的に酸素を血流に運ぶことができなくなります。この病気は通常、50歳から70歳の人が罹患します。特発性肺線維症は、間質性肺疾患（ILD）とも呼ばれる疾患群に属し、肺に炎症や瘢痕化を伴う肺の病気を指します。

特発性肺線維症の最も一般的な症状は、息切れと、乾いた咳が続くことです。また、食欲不振や徐々に体重が減少する人も少なくありません。また、酸素不足により、手足の指先が広がって丸くなる（内反症）方もいます。

世界の特発性肺線維症市場の成長を促す主な要因としては、線維性疾患の有病率の上昇や老年人口の増加などが挙げられます。また、費用対効果の高い薬剤に対する需要の高まりや、高度な治療オプションの導入も市場の成長を後押ししています。しかし、本疾患の適切な治療オプションが利用できないことが、市場の成長を制約しています。

特発性肺線維症の世界市場は、薬剤の種類、流通チャネル、地域に基づいて区分されています。薬剤の種類により、市場はピルフェニドンとニンテダニブに分けられます。流通チャネルに基づき、市場は病院薬局、小売薬局、オンラインプロバイダに分けられます。地域別では、北米、欧州、アジア太平洋、LAMEA)に分けて分析しています。

本レポートで紹介する主要企業は、AstraZeneca Plc、Biogen Inc、Boehringer Ingelheim、F. Hoffmann-La Roche、FibroGen, Inc、Mission Therapeutics、GNI Group Ltd、Galapagos NV、Biogen、Bristol-Myers Squibb Company、Shiongi Co Ltd.です。

ステークホルダーにとっての主なメリット

本調査では、世界の特発性肺線維症市場を現在の動向と将来の予測とともに詳細に分析し、差し迫った投資ポケットを解明します。
市場の成長を促進、制限する要因の包括的な分析が提供されています。
2020年から2030年までの業界の包括的な定量分析は、利害関係者が現行の市場機会を活用することを可能にするために提供されています。
業界の主要セグメントの広範な分析は、世界中で使用される特発性肺線維症の製品とエンドユーザーを理解するのに役立ちます。
主要な市場プレイヤーとその戦略は、市場の競争の見通しを理解するために分析されています。

薬剤の種類別
##ピルフェニドン
#ニンテダニブ
#販売チャネル別
##病院薬局
#小売店
#オンラインプロバイダー
#地域別
##北米
###米国
###カナダ
###メキシコ
##ヨーロッパ
###ドイツ
###フランス
###イギリス
###イタリア
###スペイン
###その他のヨーロッパ
##アジア太平洋
###中国
###日本
###インド
###オーストラリア
###韓国
###その他のアジア太平洋地域
#ラメア
###ブラジル
###サウジアラビア
###南アフリカ
###LAMEAの残りの地域


#キープレイヤー
##アストラゼネカPLC
##ブリストル・マイヤーズ スクイブ社
##ベーリンガーインゲルハイム
##GNI グループ株式会社
##F.ホフマン・ラ・ロシュ社(ジェネンテック, Inc.)
##シオンジ株式会社
##ミッション・セラピューティクス
##バイオジェン社
## ガラパゴスNV
##ファイブロジェン社

ページTOPに戻る

目次

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Top player positioning, 2020
3.4.Porter’s five forces analysis

3.4.1.Bargaining power of suppliers
3.4.2.Bargaining power of buyers
3.4.3.Threat of new entrants
3.4.4.Threat of substitutes
3.4.5.Intensity of competitive rivalry

3.5.MARKET DYNAMICS

3.5.1.Drivers

3.5.1.1.Increase in incidences of cancer across the globe
3.5.1.2.Surge in global geriatric population
3.5.1.3.Increase in cigarette smoking

3.5.2.Restraint

3.5.2.1.Lack of awareness & Proper treatment.

3.5.3.Opportunities

3.5.3.1.Increase in number of pipeline drugs
3.5.3.2.Growth opportunities in emerging markets

3.5.4.Impact analyses

3.6.COVID-19 impact analysis on market
3.7.Pipeline analyses

CHAPTER 4:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Pirfenidone

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.Nintedanib

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

CHAPTER 5:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast, by distribution channel

5.2.Hospital- pharmacies

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Retail pharmacy

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online Pharmacy

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America market size and forecast, by country
6.2.3.North America market size and forecast, by drug type
6.2.4.North America market size and forecast, by distribution channel

6.2.4.1.U.S.

6.2.4.2.U.S. market size and forecast, by drug type
6.2.4.3.U.S. market size and forecast, by distribution channel
6.2.4.4.Canada
6.2.4.5.Canada market size and forecast, by drug type
6.2.4.6.Canada market size and forecast, by distribution channel
6.2.4.7.Mexico
6.2.4.8.Mexico market size and forecast, by drug type
6.2.4.9.Mexico market size and forecast, by distribution channel

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe market size and forecast, by country
6.3.3.Europe market size and forecast, by drug type
6.3.4.Europe market size and forecast, by distribution channel

6.3.4.1.Germany.
6.3.4.2.Germany market size and forecast, by drug type
6.3.4.3.Germany market size and forecast, by distribution channel
6.3.4.4.France
6.3.4.5.France market size and forecast, by drug type
6.3.4.6.France market size and forecast, by distribution channel
6.3.4.7.UK
6.3.4.8.UK market size and forecast, by drug type
6.3.4.9.UK market size and forecast, by distribution channel
6.3.4.10.Italy
6.3.4.11.Italy market size and forecast, by drug type
6.3.4.12.Italy market size and forecast, by distribution channel
6.3.4.13.Spain
6.3.4.14.Spain market size and forecast, by drug type
6.3.4.15.Spain market size and forecast, by distribution channel
6.3.4.16.Rest of Europe
6.3.4.17.Rest of Europe market size and forecast, by drug type
6.3.4.18.Rest of Europe market size and forecast, by distribution channel

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific market size and forecast, by country
6.4.3.Asia-Pacific market size and forecast, by drug type
6.4.4.Asia-Pacific market size and forecast, by distribution channel

6.4.4.1.Japan
6.4.4.2.Japan market size and forecast, by drug type
6.4.4.3.Japan market size and forecast, by distribution channel
6.4.4.4.China
6.4.4.5.China market size and forecast, by drug type
6.4.4.6.China market size and forecast, by distribution channel
6.4.4.7.India
6.4.4.8.India market size and forecast, by drug type
6.4.4.9.India market size and forecast, by distribution channel
6.4.4.10.Australia
6.4.4.11.Australia market size and forecast, by drug type
6.4.4.12.Australia market size and forecast, by distribution channel
6.4.4.13.South Korea
6.4.4.14.South Korea market size and forecast, by drug type
6.4.4.15.South Korea market size and forecast, by distribution channel
6.4.4.16.Rest of Asia-Pacific
6.4.4.17.Rest of Asia-Pacific market size and forecast, by drug type
6.4.4.18.Rest of Asia-Pacific market size and forecast, by distribution channel

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA market size and forecast, by country
6.5.3.LAMEA market size and forecast, by drug type
6.5.4.LAMEA market size and forecast, by application

6.5.4.1.Brazil
6.5.4.2.Brazil market size and forecast, by drug type
6.5.4.3.Brazil market size and forecast, by distribution channel
6.5.4.4.Saudi Arabia
6.5.4.5.Saudi Arabia market size and forecast, by drug type
6.5.4.6.Saudi Arabia market size and forecast, by distribution channel
6.5.4.7.South Africa
6.5.4.8.South Africa market size and forecast, by drug type
6.5.4.9.South Africa market size and forecast, by distribution channel
6.5.4.10.Rest of LAMEA
6.5.4.11.Rest of LAMEA market size and forecast, by drug type
6.5.4.12.Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 7:COMPANY PROFILES

7.1.AstraZeneca Plc.

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product Portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments

7.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance

7.3.Bristol-Myers Squibb Company

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.Biogen,Inc

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.FibroGen, Inc

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.F. Hoffmann-La Roche AG

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.GNI Group Ltd.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.Galapagos NV.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.Mission Therapeutics

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio

7.10.Shionogi & Co Ltd

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance


List of Tables

LIST OF TABLES

TABLE 01.PRODUCT PIPELINE ANALYSIS (PHASE II & III)
TABLE 02.GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 03.PIRFENIDONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.NINTEDANIB MARKET, BY REGION, 2020–2030($MILLION)
TABLE 05.GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 06.HOSPITAL- PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 08.IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 09.IDIOPATHIC PULMONARY FIBROSIS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 10.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 11.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 12.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 13.U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 14.U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 15.CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 16.CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 17.MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 18.MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 19.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 20.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 21.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 22.GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 23.GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 24.FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 25.FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26.UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 27.UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28.ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 29.ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 30.SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 31.SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 32.REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 33.REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 34.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 35.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 36.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 37.JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 38.JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 40.CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41.INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 42.INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 43.AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 44.AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 46.SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47.REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 49.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 50.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 51.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 52.BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 53.BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 54.SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 55.SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 56.SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 57.SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58.REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 59.REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 61.ASTRAZENECA: OPERATING SEGMENTS
TABLE 62.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 63.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 64.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 65.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 66.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 67.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 68.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 69.BIOGEN: COMPANY SNAPSHOT
TABLE 70.BIOGEN: OPERATING SEGMENTS
TABLE 71.BIOGEN: PRODUCT PORTFOLIO
TABLE 72.FIBROGEN: COMPANY SNAPSHOT
TABLE 73.FIBROGEN: OPERATING SEGMENTS
TABLE 74.LILLY: PRODUCT PORTFOLIO
TABLE 75.ROCHE: COMPANY SNAPSHOT
TABLE 76.ROCHE: OPERATING SEGMENTS
TABLE 77.ROCHE: PRODUCT PORTFOLIO
TABLE 78.GNI: COMPANY SNAPSHOT
TABLE 79.GNI: PRODUCT SEGMENTS
TABLE 80.GNI: PRODUCT PORTFOLIO
TABLE 81.GALAPAGOS: COMPANY SNAPSHOT
TABLE 82.GALAPAGOS: OPERATING SEGMENTS
TABLE 83.GALAPAGOS: PRODUCT PORTFOLIO
TABLE 84.MISSION: COMPANY SNAPSHOT
TABLE 85.MISSION: OPERATING SEGMENTS
TABLE 86.MISSION: PRODUCT PORTFOLIO
TABLE 87.SHIONOGI: COMPANY SNAPSHOT
TABLE 88.SHIONOGI: OPERATING SEGMENTS
TABLE 89.SHIONOGI: PRODUCT TYPE PORTFOLIO


List of Figures

LIST OF FIGURES

FIGURE 01.IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLAYER POSITIONING, 2020
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH BARGAINING POWER OF BUYERS
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE THREAT OF SUBSTITUTES
FIGURE 08.MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 09.IMPACT ANALYSES
FIGURE 10.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR PIRFENIDONE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR NINTEDANIB, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR HOSPITAL- PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PROVIDER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.ASTRAZENECA: REVENUE, 2018–2020($MILLION)
FIGURE 16.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020(%)
FIGURE 17.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 18.BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 20.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 21.REVENUE, 2018–2020 ($MILLION)
FIGURE 22.BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 23.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.BIOGEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25.FIBROGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.FIBROGEN: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 27.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 29.ROCHE: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 30.GNI: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.GALAPAGOS: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.SHIONOGI: REVENUE, 2018–2020 ($MILLION)